Marijuana Chewing Gums: To Be Available in the Market Soon?

As more states come to legalize the controversial drug marijuana, many companies are also seeking to take advantage of the new trend. In line with this, AXIM Biotech has been granted a patent approval for utilizing cannabinoids as well as the commercialization of the Marijuana Chewing gums.

According to FoxBusiness, Marijuana stocks have increased in 2016, garnering an eye-catching gains of favorably over 2,000%. AXIM Biotech is a biotechnology company which focuses on research and development as well as the production of pharmaceutical, nutraceutical and cosmetic products. The company also embraces green standard for the cannabinoid bio-science through extensive research and commercialization of the up to date materials and technologies required for the improvement of every product they put into market.

Cannabinoid is a diverse chemical compound that acts as cannabinoid receptor in cells which is responsible for altering the neurotransmitter release in the human brain. There are more than a hundred kinds of cannabinoids but the most notable is the photocannabinoid tetrahydrocannabinol (THC), considered as the primary psychoactive compound of cannabis. Cannabinoids could be found in Marijuana plants which currently plays a significant role in treating a wide variety of diseases, based on the National Institute on Drug Abuse.

The company's new patent allows the company to 'provide a good delivery to all cannabinoids,' without having a psychoactive effect, AXIM CEO Dr. George Anastassov said on  FoxBusiness.Though the new patent has been approved but customers would still be needing physician's approval before ingestion.

AXIM is a pioneer with the vexed drug when they released their first alike product, CanChew in all of America's states. The said product contains 99.9% pure CBD crystals which is absorbed through the mouth. Speculations all over took place months after its release. At the moment, AXIM's new product, the MedChew RX is expected to complete the third phase of the clinical trials by the last quarter of 2017 then approval of the Food and Drug Administration and European Medicines Agency should follow. The Marijuana chewing gum would only be available in pharmaceutical supermarkets in a controlled consumption. However, Antassov expects the chewing gum to be fully registered by 2018.